Aziyo Biologics Inc - Ordinary Shares - Class A Stock

$2.05

14.23% yesterday

Nasdaq, Jul 14, 10:00 pm CET

ISIN

US05479K1060

Symbol

ELUT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Aziyo Biologics Inc - Ordinary Shares - Class A Stock price

$2.05

-14.95 87.94% 5Y

Nasdaq, Closing price Mon, Jul 14 2025

-0.34 14.23%

ISIN

US05479K1060

Symbol

ELUT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$98.3m

Enterprise Value

$105.2m

Net debt

$6.9m

Cash

$17.4m

Shares outstanding

40.9m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

3.2 | 3.4

EV/Sales

3.5 | 3.6

EV/FCF

negative

P/B

negative

Financial Health

Equity Ratio

-128.1%

Return on Equity

116.6%

ROCE

-1,209.5%

ROIC

179.8%

Debt/Equity

-0.7

Financials (TTM | estimate)

Revenue

$30.4m | $29.3m

EBITDA

$-26.2m | $-11.9m

EBIT

$-29.6m | $-24.7m

Net Income

$-57.9m | $-26.7m

Free Cash Flow

$-29.8m

Growth (TTM | estimate)

Revenue

4.9% | 20.1%

EBITDA

-31.4% | 42.7%

EBIT

-25.6% | -1.9%

Net Income

-21.4% | 50.6%

Free Cash Flow

-53.6%

EPS

$-1.5

FCF per Share

$-0.7

Short interest

0.1%

Employees

Rev per Employee

$480.0k

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Aziyo Biologics Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Aziyo Biologics Inc - Ordinary Shares - Class A forecast:

7x Buy

88%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Aziyo Biologics Inc - Ordinary Shares - Class A forecast:

Buy

88%

Hold

13%

Analyst Estimates with Stock Price Targets

Financial data from Aziyo Biologics Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	30 30	5% 5% 100%
- Direct Costs	17 17	15% 15% 57%
Gross Profit	13 13	50% 50% 43%
- Selling and Administrative Expenses	38 38	36% 36% 125%
- Research and Development Expense	4.69 4.69	10% 10% 15%
EBITDA	-26 -26	31% 31% -86%
- Depreciation and Amortization	3.46 3.46	5% 5% 11%
EBIT (Operating Income) EBIT	-30 -30	26% 26% -97%
Net Profit	-58 -58	21% 21% -190%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Aziyo Biologics Inc - Ordinary Shares - Class A Stock News

Neutral

GlobeNewsWire

●

13 days ago

New Evidence Supports the Value of Elutia's Antibiotic-Eluting Platform for Implantable Devices

— The EluPro BioEnvelope findings demonstrate the bioactive properties and superior healing response compared to synthetic materials for cardiac implantable electronic devices (CIEDs) —

Neutral

GlobeNewsWire

●

18 days ago

Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards

Recognition highlights EluPro™ Antibiotic-Eluting BioEnvelope's impact on device protection for cardiac implantable electronic devices (CIEDs) and neurostimulators SILVER SPRING, Md., June 26, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, has been recognized with two prestigious honors—Innovation and Product La...

Neutral

GlobeNewsWire

●

about 2 months ago

Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method

— Innovative approach accelerates new product development and testing — — Innovative approach accelerates new product development and testing —

More Aziyo Biologics Inc - Ordinary Shares - Class A News

Company Profile

Aziyo Biologics, Inc. operates as a biotechnology company which focuses on regenerative medicine in areas such as cardiology, orthopedics and other medical specialties. It offers cardiac device envelope, vascular surgery, cardiothoracic repair, orthopedics and spine, sports medicine, dermal, and wound care. The company was founded on August 6, 2015 and is headquartered in Silver Spring, MD.

Head office	United States
CEO	Charles Mills
Employees	51
Founded	2015
Website	elutia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now